natgillin/translations-raw huggingface dataset:
Den farmakokinetiske profil for lutetium (177Lu)-oxodotreotid hos patienter med svær nyrebeskadigelse (kreatinin-clearance < 30 ml/min) er ikke blevet undersøgt, og derfor er behandling af disse patienter med Lutathera kontraindiceret (se pkt. 
The pharmacokinetic profile of lutetium (177Lu) oxodotreotide in patients with severe renal impairment (creatinine clearance < 30 mL/min) has not been studied, therefore treatment with Lutathera in those patients is contraindicated (see section 4.3).
Patienter med urininkontinens 
Patients with urinary incontinence
Myelodisplastisk syndrom og akut leukæmi 
Myelodisplastic syndrome and acute leukaemia
Administration af aminosyreopløsning skal startes 30 minutter før Lutathera-infusion med en infusionshastighed på 250-550 ml/t (afhængig af opløsningstype). 
Administration of the amino acid solution should be initiated 30 minutes before Lutathera infusion, with an infusion rate of 250 to 550 mL/h (depending on the solution type).
Ved 4 timer efter indgift viser fordelingsmønsteret af lutetium (177Lu)-oxodotreotid en hurtig optagelse i nyrer, tumorlæsioner, lever og milt og hos nogle patienter i hypofysen og i skjoldbruskkirtlen. 
Organ uptake At 4 hours after administration, the distribution pattern of lutetium (177Lu) oxodotreotide shows a rapid uptake in kidneys, tumour lesions, liver and spleen, and in some patients in the pituitary gland and in the thyroid.
Klar, farveløst type I-hætteglas, lukket med en brombutylgummiprop og aluminiumsforsegling. 
Clear colourless Type I glass vial, closed with a bromobutyl rubber stopper and aluminium seal.
Med henblik på nyrebeskyttelsesformål skal en aminosyreopløsning administreres intravenøst i 4 timer. 
For renal protection purpose, an amino acid solution must be administered intravenously during 4 hours.
På skæringsdatoen for den post-hoc statistiske analyse (30. juni 2016), var antallet af centralt konfirmerede sygdomsprogressioner eller dødsfald 30 hændelser i Lutathera-armen og 78 hændelser i octreotid LAR-armen (Tabel 9). 
At the cut-off date for post-hoc statistical analysis (30 June 2016), the number of centrally confirmed disease progressions or deaths was 30 events in the Lutathera arm and 78 events in the octreotide LAR arm (Table 9).
Meldola (FC) Italien 
Meldola (FC) Italy
Den visuelle inspektion skal udføres under en beskyttelsesafskærmning for at undgå radioaktiv stråling. 
The visual inspection of the solution should be performed under a shielded screen for radioprotection purposes.
På tidspunktet for den endelige PFS statistiske analyse pr. protokol (skæringsdato den. 24 juli 2015), var antallet af centralt bekræftede sygdomsprogressioner eller dødsfald 21 hændelser i Lutatheraarmen og 70 hændelser i octreotid-LAR-armen (Tabel 8). 
At the time of final per-protocol PFS statistical analysis (cut-off date 24 July 2015), the number of centrally confirmed disease progressions or deaths was 21 events in the Lutathera arm and 70 events in the octreotide LAR arm (Table 8).
Nyrefunktionen, bestemt i form af serum-kreatinin og beregnet kreatinin-clearance, skal vurderes ved baseline samt under og mindst et år efter behandlingen (se pkt. 
Renal function as determined by serum creatinine and calculated creatinine clearance must be assessed at baseline, during and at least for the first year after treatment (see section 4.2).
• Den korte nål indsættes i Lutathera-hætteglasset, uden at komme i kontakt med den radiofarmaceutiske opløsning. 
• The short needle should be inserted into the Lutathera vial, so that it does not touch the radiopharmaceutical solution.
Virkningsmekanisme Lutetium (177Lu)-oxodotreotid har en høj affinitet for somatostatinreceptorer af subtype 2 (sst2). 
Mechanism of action Lutetium (177Lu) oxodotreotide has a high affinity for subtype 2 somatostatin receptors (sst2).
Muskuloskeletale smerter8 Muskelspasmer 
Musculoskeletal pain8 Muscle spasms
Transchelering af lutetium fra lutetium (175Lu)-oxodotreotid i serumproteiner er ikke blevet observeret. 
Transchelation of lutetium from lutetium (175Lu) oxodotreotide into serum proteins has not been observed.
CR = Komplet respons PR = Delvis respons; SD = Stabil sygdom ORR = Objektiv respons (CR + PR) DoR = Responsvarighed * Inkluderer fortarm, middttarm og bagtarm Midgut, **fortarms NET'er bortset fra bronkial og bugspytkirtel 
CR = Complete response; PR = Partial response; SD = Stable disease; ORR = Objective response (CR+PR); DoR = Duration of response * Includes Foregut, Midgut and Hindgut; **Foregut NETs other than bronchial and pancreatic
Under behandling med Lutathera, og som minimum i de følgende 6 måneder efter afbrydelse af behandlingen, skal der træffes passende foranstaltninger for at undgå graviditet. 
During treatment with Lutathera and for a minimum of the following 6 months after the end of the treatment, appropriate measures must be taken to avoid pregnancy; this applies to patients of both genders.
Svimmelhed Dysgeusi Hovedpine10 
Dizziness Dysgeusia Headache10
Vær særlig forsigtig med Lutathera - Hvis din nyre eller urinveje ikke er korrekt udviklet 
Take special care with Lutathera - if your kidney or urinary track are not correctly developed - if you are suffering from urinary incontinence
Det er ikke sandsynligt, at du vil få en overdosis, da du får en enkel dosis under kontrollerede forhold af den nuklearmedicinske læge, der har tilsyn med indgiften. 
If you have been given more Lutathera than you should An overdose is unlikely because you will only receive a single dose of Lutathera precisely controlled by the nuclear medicine doctor supervising the administration procedure.
oxodotreotid via tubuli renales (nyrekanalerne), hvilket resulterer i en signifikant reduktion af nyrebestrålingsdosis (se pkt. 
oxodotreotide through the proximal tubules, resulting in a significant reduction in the kidney radiation dose (see section 4.2).
Baseret på de data, der blev indsamlet i fase III-studierne i Erasmus fase I/II og NETTER-1, elimineres lutetium (177Lu)-oxodotreotid primært via udskillelse gennem nyrerne: ca. 60 % af lægemidlet udskilles i urinen inden for 24 timer og ca. 65 % inden for 48 timer efter indgift. 
Based on the data collected during the Erasmus phase I/II and NETTER-1 phase III studies, lutetium (177Lu) oxodotreotide is primarily eliminated by renal excretion: about 60% of the medicinal product is eliminated in the urine within 24 hours, and about 65% within 48 hours following the administration.
Opløsningsniveauet i hætteglasset skal forblive konstant under hele infusionen. 
The level of solution in the vial should remain constant during the entire infusion.
Den samlede mængde radioaktivitet pr. enkeltdosishætteglas er 7.400 MBq på infusionsdatoen ogtidspunktet. 
The total amount of radioactivity per single dose vial is 7,400 MBq at the date and time of infusion.
Lutathera skal administreres via langsom intravenøs infusion i løbet af ca. 30 minutter ledsaget af aminosyreopløsning administreret via modsidig intravenøs infusion. 
Lutathera must be administered by slow intravenous infusion over approximately 30 minutes, concomitantly with amino acid solution administered by contralateral intravenous infusion.
Administration af Lutathera skal påbegyndes ved først at åbne for slangeforbindelsen forbundet med det venøse kateter i patientens arm og derefter ved at åbne for infusionssættet forbundet med posen med natriumklorid 9 mg/ml (0,9 %) infusionsvæske, opløsning. 
Lutathera administration should be initiated by opening first the tubing line connected to the patient's peripheral vein, and then, by opening the infusion set connected to the bag of sodium chloride 9 mg/mL (0.9%) solution for injection.
En konstant, indvendigt hætteglastryk skal opretholdes under hele infusionen. 
Constant intra-vial pressure should be maintained during the entire infusion.
Administration af langtidsvirkende somatostatinanaloger bør undgås i 30 dage før administration af Lutathera. 
Administration of long acting somatostatin analogues should be avoided within 30 days prior to the administration of Lutathera.
• Mild til moderat kronisk nyrelidelse med kreatinin-clearance ≥ 50 ml/min; 
• Mild to moderate chronic kidney disease with creatinine clearance ≥ 50 mL/min;
Katetrene forbindes med infusionssættene (et sæt til administration af Lutathera, og et sæt til administration af aminosyreopløsning). 
The catheters should be connected to the infusion sets (one for Lutathera, one for amino acid solution).
Lysinindhold 
Lysine content
Nøje afvejning af den administrerede aktivitet er nødvendig hos sådanne patienter, da der er mulighed for øget strålingseksponering. 
Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients.
Lutathera skal altid injiceres via et intravenøst kateter anlagt udelukkende til infusion af dette. 
Lutathera should always be infused through an intravenous catheter placed exclusively for its infusion.
Derfor bør gentagen administration af høje doser af glukokortikosteroider under behandling med Lutathera, undgås af sikkerhedshensyn. 
Therefore, as a matter of cautiousness, repeated administration of high-doses of glucocorticosteroids should be avoided during Lutathera treatment.
For at sikre komplet administration skal der opretholdes et jævnt tryk i Lutathera-hætteglasset. 
To ensure complete administration, the Lutathera vial should be kept under even pressure.
Konjunktivitis Luftvejsinfektion Cystitis 
Conjunctivitis Respiratory tract infection Cystitis
Aminosyreopløsning skal administreres i løbet af et tidsrum på 4 timer. 
Amino acid solution should be administered over 4 hour time span.
Det anbefales, at plejepersonalet bruger engangshandsker i 7 dage efter administrationen i forbindelse med assistance på badeværelset. 
It is recommended that when providing assistance in the bathroom, the care provider wears disposable gloves for 7 days after administration.
Brug af Lutathera er kontraindiceret hos patienter med alvorlig nyresvigt (se pkt. 
The use of Lutathera is contraindicated in patients with severe kidney failure (see section 4.3).
Analyser af højpræstationsvæskekromatografi (HPLC) udført på urinprøver indsamlet op til 48 timer efter infusion viste radiokemisk renhed af lutetium (177Lu)-oxodotreotid i nærheden af 100 % i de fleste analyserede prøver (hvor den laveste radiokemiske renhedsværdi var større end 92 %), hvilket indikerer, at forbindelsen hovedsageligt elimineres i urin som intakt forbindelse. 
The high performance liquid chromatography (HPLC) analyses performed on urine samples collected up to 48 hours post infusion showed lutetium (177Lu) oxodotreotide radiochemical purity close to 100% in most of the analysed samples (with lowest radiochemical purity value being greater than 92%), indicating that the compound is eliminated in urine mainly as intact compound.
ANVENDELSESMÅDE OG ADMINISTRATIONSVEJ(E) Hætteglas med enkelt dosis. 
METHOD AND ROUTE(S) OF ADMINISTRATION Single-dose vial.
Hvis hætteglassets integritet på noget tidspunkt brydes under klargøring af lægemidlet, må det ikke anvendes. 
If at any time in the preparation of this medicinal product the integrity of this vial is compromised, it should not be used.
Fareforholdet for Lutathera var 0,18 (95 % CI: 0,11 - 0,29), hvilket indikerer 82 % reduktion i risikoen for, at en patient oplever progressin eller dør under Lutathera sammenlignet med octreotid LAR. 
The hazard ratio for Lutathera was 0.18 (95% CI: 0.11 - 0.29), indicating 82% reduction in the risk for a patient to progress or die under Lutathera compared to octreotide LAR.
Under infusionen skal den radioaktive udstråling fra patientens thorax øges gradvist, mens infusionen fra Lutathera-hætteglasset reduceres. 
During the infusion, the radioactivity emission from the patient's thorax should steadily increase while the one from the Lutathera vial should decrease.
Bronkial 
Bronchial
Almindelig (kan påvirke op til 1 ud af 10 personer) Lavt antal hvide blodlegemer (leukopeni eller neutropeni), muskelsmerter, midlertidigt delvist hårtab (alopeci), abdominal distension (oppustethed), diarré, svimmelhed, reaktion på injektionsstedet eller hævelse, smagsforstyrrelser, smerte på injektionsstedet, hovedpine, højt eller lavt blodtryk, perifert ødem, unormale resultater af nyretest (forhøjet kreatinin), mavesmerter (generelt og øvre), forstoppelse, unormale resultater af levertest, rødme og hedeture, øget sukkerindhold i blod, besvimelse, nyresvigt (herunder akut skade), dehydrering, halsbrand (dyspepsi), blod i urinen, unormale urinprøveresutater (forekomst af serumproteiner), nedsat funktion af skjoldbruskkirtlen, åndenød, mavebetændelse (gastritis ), unormalt høje mængder galpigment (bilirubin) i blodet (hyperbilirubinæmi), unormale blodprøveresultater (hypomagnesæmi og hyponatriæmi), influenzalignende sygdom, kuldegysninger, knoglemarvscancer (myelodysplastisk syndrom), blodtransfusion. 
Low white blood cell count (leukopenia or neutropenia), muscle pain, temporal partial hair loss (alopecia), abdominal distension (feeling bloated), diarrhoea, dizziness, injection site reaction or swelling, disturbed taste, pain in the site of injection, headache, high or low blood pressure, peripheral oedema, abnormal results of renal blood test (increased creatinine), abdominal pain (general and upper), constipation, abnormal results of liver blood test, flushing and hot flushes, increased sugar level in the blood, fainting, renal failure (including acute injury), dehydration, heartburn (dyspepsia), blood in urine, abnormal results of urine test (presence of serum proteins), decrease in function of thyroid, shortness of breath, inflammation of stomach (gastritis), abnormally high amounts of bile pigment (bilirubin) in the blood (Hyperbilirubinemia), abnormal results of blood test (Hypomagnesaemia and hyponatraemia), influenza like illness, chills, bone marrow cancer (myelodysplastic syndrome), blood transfusion.
Eddikesyre, natriumacetat, gentisinsyre, ascorbinsyre, pentinsyre, natriumchlorid 9 mg/ml injektion, natriumhydroxid, vand til injektionsvæsker. 
Acetic acid, sodium acetate, gentisic acid, ascorbic acid, pentetic acid, sodium chloride 9 mg/mL injection, sodium hydroxide, water for injections.
Hvert hætteglas indeholder et volumen varierende fra 20,5 til 25,0 ml opløsning svarende til en aktivitet på 7.400 MBq på dato og tidspunkt for infusion. 
Each vial contains a volume varying from 20.5 to 25.0 mL of solution corresponding to an activity of 7,400 MBq at date and time of infusion.
- Øvrige indholdsstoffer: Eddikesyre, natriumacetat, gentisinsyre, ascorbinsyre, diethylentriaminpentaeddikesyre (DTPA), natriumchlorid 9 mg/ml (0,9 %) injektionsvæske, opløsning, vand til injektionsvæsker (se afsnit 2 "Lutathera indeholder natrium ”). 
- The other ingredients are: acetic acid, sodium acetate, gentisic acid, ascorbic acid, diethylene triamine pentaacetic acid (DTPA), sodium chloride 9 mg/mL (0.9%) solution for injection, water for injections (see section 2 “Lutathera contains sodium”).
Lutathera er en klar og farveløs infusionsvæske, der leveres i et farveløst hætteglas lukket med en gummiprop og forseglet med en aluminiumskapsel. 
What Lutathera looks like and contents of the pack Lutathera is a clear and colourless solution for infusion, supplied in a colourless glass vial closed with a rubber stopper and sealed with an aluminium capsule.
Benigne, maligne og uspecificerede neoplasmer (inkl. 
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Tiltag 
Action
• Nyresvigt med kreatinin-clearance < 30 ml/min 
• Kidney failure with creatinine clearance < 30 mL/min
PFS og OS observeret i Erasmus fase I/II-studiet hos hollandske patienter med GEP og bronkial NET - (FAS, N = 360) 
PFS and OS observed in the Erasmus phase I/II study in Dutch patients with GEP and bronchial NET - (FAS, N=360)
Amning skal stoppes. 
Breast-feeding must be stopped.
Hævet ansigt Hyperhidrose Generaliseret pruritus 
Swelling face Hyperhidrosis Pruritus generalized
Hazard ratioen for Lutathera var 0,21 (95 % CI: 0.14 - 0.33), hvilket indikerede en reduktion på 79 % for, at en patient ville progrediere eller dø under behandling med Lutathera, sammenlignet med octreotid LAR. 
The hazard ratio for Lutathera was 0.21 (95% CI: 0.14 - 0.33), indicating 79% reduction in the risk for a patient to progress or die under Lutathera compared to octreotide LAR.
Orofaryngeal smerte Pleuraeffusion Forøget sputum Kvælningsfornemmelse 
Oropharyngeal pain Pleural effusion Sputum increased Choecking sensation
Lægemidlet skal injiceres via et intravenøst kateter placeret i venen udelukkende til infusion af dette. 
The medicinal product should be infused through an intravenous catheter placed in the vein exclusively for its infusion.
8 Omfatter ledsygdom, smerter i ekstremitet, rygsmerter, knoglesmerter, flankesmerter, muskuloskeletale brystsmerter og nakkesmerter 
8 Includes Arthralgia, Pain in extremity, Back pain, Bone pain, Flank pain, Musculoskeletal chest pain and Neck pain
Sådan får du Lutathera 4. 
How Lutathera is used 4.
Om nødvendigt kan patienterne behandles med korttidsvirkende somatostatinanaloger i 4 uger før administration af Lutathera og op til 24 timer før administration af Lutathera. 
If necessary, patients may be treated with short acting somatostatin analogues during the 4 weeks preceding Lutathera administration, until 24 hours before the administration of Lutathera.
Hvis du oplever nogen bivirkninger, skal du tale med din nuklearmedicinske læge. 
- If you get any side effects, talk to your nuclear medicine doctor.
Osteogene celler 
Osteogenic Cells Skin
Denne evidens bekræfter det, der tidligere er blevet observeret i Erasmus fase I/II-studiet, hvor HPLCanalyse af en urinprøve indsamlet 1 time efter administration af lutetium (177Lu)-oxodotreotid fra en patient, der modtog 1,85 MBq lutetium (177Lu)-oxodotreotid viste, at hovedparten (91 %) udskilles uændret. 
This evidence confirms what has been previously observed in the Erasmus phase I/II study, in which HPLC analysis of a urine specimen collected 1 hour post administration of lutetium (177Lu) oxodotreotide from one patient receiving 1.85 MBq of lutetium (177Lu) oxodotreotide indicated that the main portion (91%) was excreted unchanged.
6,2 Uforligneligheder 
6.2 Incompatibilities
• Morfologiske anormaliteter i nyrer eller urinveje; 
• Renal or urinary tract morphological abnormalities;
Stafylokokinfektioner Streptokokbakteriæmi 
Staphylococcal infections Streptococcal bacteraemia
En opdatering gennemført omkring et år efter den 30. juni 2016 viste en lignende tendens med 28 dødsfald i Lutathera-armen og 43 i octreotid LAR 60 mg-armen, et HR på 0,536 og et median OS på 27,4 måneder i octreotid LAR-armen og var stadig ikke pnået i Lutathera-armen. 
OS median was 27.4 months in octreotide LAR arm and was not reached in Lutathera arm. An update conducted about one year after (30 June 2016) showed similar trend with 28 deaths in the Lutathera arm and 43 in octreotide LAR 60 mg arm, an HR of 0.536, and a median OS of 27.4 months in octreotide LAR arm and still not reached in Lutathera arm.
Hypertension7 Rødmen Hedeture Hypotension 
Hypertension7 Flushing Hot flush Hypotension
Administrerede midler 
Administered agents
Kvalme, opkastning, træthed, lavt blodpladeantal (trombocytopeni), lavt antal hvide blodlegemer (lymfopeni), lavt antal røde blodlegemer (anæmi), nedsat appetit, nedsat antal blodlegemer (pancytopeni) 
Nausea, vomiting, fatigue, low platelet count (thrombocytopenia), low white blood cell count (lymphopenia), low red cell count (anaemia), decreased appetite, decreased all blood cell count (pancytopenia)
Mængde 
Amount
Bronkial Bugspytkirtel Fortarm** Midttarm Bagtarm 
Bronchial Pancreatic Foregut** Midgut Hindgut
Hold poserne væk fra børn og dyr. 
Keep the specific plastic trash bags separated from the other trash; keep the bags away from children and animals.
Indehaver af markedsføringstilladelsen Advanced Accelerator Applications 20 rue Diesel 
Marketing Authorisation Holder Advanced Accelerator Applications 20 rue Diesel
Tabel 10: Bedste respons, ORR og DoR observeret i Erasmus fase I/ II-studiet hos hollandske patienter med GEP og bronkiale NET - (FAS, N = 360) 
Best response, ORR and DoR observed in the Erasmus phase I/II study in Dutch patients with GEP and bronchial NETs - (FAS, N=360)
− En tang (til håndtering af Lutathera-hætteglas) 
− A pair of tongs (for Lutathera vial handling)
Øget blodkreatinfosfokinase Øget blodlaktatdehydrogenase Blodkatecholaminer Øget C-reaktivt protein 
Blood catecholamines c-reactive protein increased
Analyse af urinprøver af 20 fra patienter inkluderet i NETTER - 1-fase III dosimetri, farmakokinetisk og EKG-substudiet indikerer, at lutetium (177Lu)-oxodotreotid metabliseres dårligt og hovedsageligt udskilles som intakt forbindelse gennem nyrerne. 
There is evidence , from the analysis of urine samples of 20 patients included in the NETTER-1 phase III Dosimetry, pharmacokinetic and ECG substudy, that lutetium (177Lu) oxodotreotide is poorly metabolized and is excreted mainly as intact compound by renal route.
PFS Kaplan - Meier-grafen for det fulde analysesæt (FAS) ved skæringsdatoen den 30. juni 2016 er afbildet i Figur 4 
The PFS Kaplan-Meier graph for the full analysis set (FAS) at the cut-off date 30 June 2016 is depicted in Figure 4.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE BEHOLDER MED BLYAFSKÆRMNING 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING LEAD SHIELDING CONTAINER
• Nyresvigt med kreatinin-clearance < 50 ml/min; 
• Kidney failure with creatinine clearance < 50 mL/min;
• Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne anført i pkt. 
• Hypersensitivity to the active substance, to any of the excipients listed in section 6.1.
Under infusionen øger tilførslen af natriumklorid 9 mg/ml (0,9 %) infusionsvæske, opløsning trykket i Lutathera-hætteglasset, hvilket fremskynder tilførslen af Lutathera til det forhåndsanlagte venøse kateter i patientens arm. 
During the infusion, the flow of sodium chloride 9 mg/mL (0.9%) solution for injection increases the pressure in the Lutathera vial, facilitating the flow of Lutathera into the catheter inserted in the patient's peripheral vein.
Den nødvendige volumen af natriumklorid 9 mg/ml (0,9 %) infusionsvæske, opløsning til fuldførelse af infusionen kan variere. 
The volume of sodium chloride 9 mg/mL (0.9%) solution for injection necessary to complete the infusion may vary.
Lutathera indeholder følgende: - Aktivt stof: lutetium (177Lu)-oxodotreotid. 
What Lutathera contains - The active substance is lutetium (177Lu) oxodotreotide.
Ved administration af radioaktive lægemidler udsættes andre personer for risiko for ydre bestråling eller kontaminering fra spild af urin, opkast, blod osv. Der skal derfor træffes forholdsregler til beskyttelse mod stråling i overensstemmelse med nationale bestemmelser. 
The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting etc.
Tabel over bivirkninger Bivirkningerne er angivet i henhold til hyppigheden og systemorganklasse iht. 
Tabulated list of adverse reactions The adverse reactions are listed in Table 7 according to the frequency and the MedDRA System Organ
4.4 for anvisninger i forberedelse af patienten. 
For patient preparation, see section 4.4.
Før Lutathera-infusionen genoptages er det påkrævet at anvende et nyt kateter og, om muligt, at anlægge det til modsidig, venøs adgang. 
To continue Lutathera infusion, it is mandatory to use a new catheter possibly placing it in a contralateral venous access.
Patienten skal opfordres til at lade vandet så ofte som muligt efter administration med Lutathera. 
The patient should be encouraged to urinate as much as possible after Lutathera adminiastration.
hvis patienten ønsker at få børn efter behandling. 
Genetic consultation is recommended if the patient wishes to have children after treatment.
Volumetrisk aktivitet på kalibreringstidspunktet: 370 MBq/ml - {DD/MM/ÅÅÅÅ tt:mm UTC} 
Volumetric activity at calibration time: 370 MBq/mL - {DD/MM/YYYY hh:mm UTC}